FDA's Concerns With Unapproved GLP1 Drugs Used for Weight Loss

Direct Answer

The FDA has directly warned that unapproved versions of GLP1 (GLP-1) drugs, including semaglutide and tirzepatide, carry real, documented risks, since they haven't undergone the agency's standard review for safety, effectiveness, and quality before reaching patients. This page summarizes the FDA's actual, current concerns and guidance.

Why This Matters

The FDA is aware that patients and healthcare professionals may turn to unapproved GLP1 drug versions, and the agency has been direct that this carries real risk precisely because these versions skip the standard regulatory review process entirely.

FDA Recommendations for Patients and Providers

Compounded drugs should only be used when a patient's medical need genuinely can't be met by an FDA-approved drug. The FDA recommends obtaining prescriptions from a doctor and filling them at a state-licensed pharmacy, using the agency's BeSafeRx resources to verify safe online purchasing, and contacting the compounder or telehealth platform directly with any questions about instructions or labeling.

Real Warning Signs of an Unsafe Telehealth Source

The FDA has outlined specific, real red flags: a provider claiming a compounded drug is identical to the FDA-approved version, prices that seem too good to be true, medication that arrives looking different than expected or in damaged packaging, no licensed-physician screening before dispensing, no licensed doctor available afterward for questions, and labeling errors or unverifiable pharmacy names or addresses.

Retatrutide and Cagrilintide Cannot Legally Be Compounded

Under federal law, retatrutide and cagrilintide cannot be used in compounding, they are not components of any FDA-approved drug and have not been found safe and effective for any condition. The FDA has issued warnings directly to telehealth companies marketing these substances, to active pharmaceutical ingredient distributors selling them, and to outsourcing facilities repackaging retatrutide.

Real, Documented Adverse Event Numbers

As of May 31, 2026, the FDA has received 990 adverse event reports associated with compounded semaglutide, and more than 730 associated with compounded tirzepatide. The agency notes federal law doesn't require most state-licensed pharmacies to report adverse events, meaning actual numbers are likely higher than reported. Documented issues include dosing errors from incorrect self-administered measurements, in some cases involving healthcare providers miscalculating doses, and instances of patients receiving doses beyond FDA-approved labeling.

Salt Forms Should Not Be Used to Compound Semaglutide

The FDA has flagged that some compounders sell semaglutide salt forms, including semaglutide sodium and semaglutide acetate, different active ingredients than those used in FDA-approved drugs. The agency has no data confirming these salts share the same chemical and pharmacologic properties as the approved active ingredient, and is not aware of any lawful basis for their use in compounding.

Counterfeit and Fraudulent Products

The FDA has confirmed real, documented cases of counterfeit Ozempic and fraudulent compounded semaglutide and tirzepatide products, some labeled with pharmacy names that don't actually exist, others falsely bearing the names of real, licensed pharmacies that never compounded the product. In one confirmed case, an adverse event, including injection-site redness, swelling, pain, and a red lump, was linked to a product falsely labeled as coming from a pharmacy that never actually made it.

Products Falsely Labeled "Not for Human Consumption"

The FDA has separately warned companies illegally selling semaglutide, tirzepatide, and retatrutide falsely labeled "for research purposes" or "not for human consumption," while still providing human dosing instructions directly to consumers, products of unknown quality the agency directly urges against purchasing.

A Real, Practical Storage Concern

Injectable GLP1 drugs require refrigeration per their labeling. The FDA has received real complaints of compounded products arriving warm or with inadequate ice packs. The agency's direct guidance: don't use an injectable GLP1 drug that arrives warm or inadequately refrigerated, since this can affect the medication's quality and safety.

FDA Actions at the Border

The FDA has established an import alert (Green List 66-80) to help stop GLP-1 active pharmaceutical ingredients with potential quality concerns from entering the U.S. supply chain, applying specifically to non-compliant foreign manufacturers, not to compliant API sources, and not creating new limits on legal compounding itself.

How to Report a Problem

The FDA encourages healthcare professionals, patients, and compounders to report adverse events or quality problems through its MedWatch program, online, by downloading and faxing the reporting form to 1-800-FDA-0178, or by contacting the CDER Division of Drug Information directly at druginfo@fda.hhs.gov or 855-543-3784.

Five Categories, Clearly Distinguished

These terms get used loosely, but they mean genuinely different things: FDA-approved medications (Ozempic, Wegovy, Mounjaro, Zepbound, Rybelsus, Saxenda, Trulicity) have completed full regulatory review. Compounded drugs are legally permitted only when a patient's specific medical need can't be met by an approved drug, and are not themselves FDA-reviewed. Investigational drugs, like retatrutide, remain under active clinical trial and aren't legally available for compounding or general prescription at all. Counterfeit products falsely claim to be an authentic, approved medication. Illegally marketed products, including those falsely labeled "not for human consumption," are sold outside any legitimate regulatory pathway entirely. Confusing any of these categories with another is exactly where real patient risk tends to originate.

How to Identify a Legitimate GLP1 Prescription

A legitimate prescription involves a real, licensed healthcare provider who has actually evaluated you, either in person or through a real telehealth screening, before prescribing. The medication should come from a state-licensed pharmacy, arrive with proper labeling and instructions, and match what you'd expect based on your provider's discussion with you, correct drug name, correct dose, intact packaging.

Questions to Ask Your Doctor or Pharmacist

Worth asking directly: is this medication FDA-approved or compounded, and if compounded, why is that the appropriate option for my situation specifically? What pharmacy is actually compounding or dispensing this? What should the packaging and labeling look like when it arrives? Who do I contact if something looks wrong?

What to Do If Your GLP1 Medication Arrives Warm or Damaged

Don't use it. Contact the pharmacy or telehealth platform directly to report the issue and request a replacement, and consider reporting the incident to the FDA's MedWatch program, since temperature-compromised injectable medication can lose effectiveness or safety even if it looks visually normal.

What to Do If You Suspect a Counterfeit Medication

Stop using the product, don't discard the packaging or remaining medication, and contact both your prescribing provider and the FDA's MedWatch program directly. If you purchased it from an online source, keep records of that transaction, this documentation matters for both your own safety follow-up and the FDA's broader investigation into counterfeit sources.

GLP1 Safety FAQ

Is compounded GLP1 automatically unsafe? No. Compounding itself is a legal, legitimate practice when a patient's medical need genuinely isn't met by an approved drug. The real risk comes from unregulated review, dosing inconsistency, and fraudulent sourcing, not from compounding as a category.

Is retatrutide FDA-approved? No, it remains investigational, and it cannot legally be compounded under federal law.

How common are adverse events from compounded GLP1 drugs? The FDA had received 990 reports for compounded semaglutide and over 730 for compounded tirzepatide as of May 31, 2026, likely an undercount given inconsistent reporting requirements.

Can I buy GLP1 medication online safely? Only through a state-licensed pharmacy with a real prescription from a provider who has actually evaluated you; the FDA's BeSafeRx resource can help verify a specific online pharmacy.

What if my telehealth provider doesn't have a licensed doctor available after I receive my medication? That's a real, documented FDA red flag, worth treating as a genuine warning sign about that specific provider.

Bottom Line

The FDA's concerns here are real, specific, and documented, not general caution. If you're using a compounded or non-standard GLP1 product, verifying your source directly against these warning signs is a real, concrete safety step worth taking.

References

• U.S. Food and Drug Administration: FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss

For the broader overview of what GLP1 and GLP-1 mean and how these medications work, see DietApp's main GLP1 resource page. For the current status of FDA compounding regulation specifically, see DietApp's explainer on the FDA's 503B proposal.

For a full look at GLP1 medication cost, insurance, and access alongside these safety considerations, see DietApp's Understanding GLP1 Drugs: Cost, Safety, and Access in Context.

Explore More

Explore the full GLP-1 Tracker knowledge base on DietApp.com

About DietApp.com

DietApp.com combines evidence-based GLP-1 medication education with practical treatment tracking tools. This article is for general informational purposes and is not medical advice.